J Korean Soc Ther Radiol.  1994 Feb;12(1):43-50.

Radiation Therapy in Malignant Tumors of the Parotid Gland

Affiliations
  • 1Department of Therapeutic Radiology, Seoul National University, College of Medicine, Seoul, Korea.
  • 2Department of Otolaryngology, Seoul National University, College of Medicine, Seoul, Korea.

Abstract

A retrospective analysis was performed on 55 patients with malignant parotid tumor who were treated with radiation therapy between March, 1979 and July, 1989. Of these patients, 8 patients received radiation therapy(RT) alone and 47 patients were treated with combined operation and radiation therapy(OP+RT). The follow-up period of the survivors ranged form 1 to 129 months with a median of 48 months. The common histologic types were mucoepidermoid carcinoma (25 cases), malignant mixed tumor(12 cases), adenoid cystic carcinoma(6 cases). The 5 and 10 year local control rate were 69.8% and 65.7% in all patients. In OP+RT group, prognostic factors related to local control were histologic grade, tumor size, lymph node metastasis. Resection of facial nerve did not affect the local control rate significantly(p=0.129). Distant metastasis developed in 23.6% of patients, mostly to the lung. Actuarial overall survival rate was 72.2% at 10 years and formed plateau after 5 years. Disease-free (NED) survival rate was 49.4% at 10 years and was better achieved in OP+RT group and low grade lesions. Based on our result, a well planned postoperative RT following parotidectomy is highly efficacious in controlling malignant tumors of the parotid gland and preservation of facial nerve.

Keyword

Malignant parotid tumor; Radiation therapy; Prognostic factor; Facial nerve

MeSH Terms

Adenoids
Carcinoma, Mucoepidermoid
Facial Nerve
Follow-Up Studies
Humans
Lung
Lymph Nodes
Neoplasm Metastasis
Parotid Gland*
Retrospective Studies
Survival Rate
Survivors
Full Text Links
  • JKSTR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr